Results 111 to 120 of about 13,785 (292)

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

open access: yesMolecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen   +9 more
wiley   +1 more source

Calculus of variations: A differential form approach

open access: yes
We study integrals of the form integral(Omega) f(d omega(1), ..., d omega(m)), where m >= 1 is a given integer, 1 R is a continuous function. We introduce the appropriate notions of convexity, namely vectorial ext.
Sil, Swarnendu
core   +1 more source

Some new applications of the fractional integral and four-parameter Mittag-Leffler function.

open access: yesPLoS ONE
The article reveals new applications of the four-parameter Mittag-Leffler function (MLF) in geometric function theory (GFT), using fractional calculus notions.
Ahmad A Abubaker   +3 more
doaj   +1 more source

Interpreting the effects of DNA polymerase variants at the structural level

open access: yesMolecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi   +7 more
wiley   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Transition probabilities for diffusion equations by means of path integrals. [PDF]

open access: yes
In this paper, we investigate the transition probabilities for diffusion processes. In a first part, we show how transition probabilities for rather general diffusion processes can always be expressed by means of a path integral.
Goovaerts, Marc   +2 more
core  

Milne-Type Inequalities in the Context of Conformable Fractional Multiplicative Integrals

open access: yesJournal of Function Spaces
This paper examines Milne inequalities in the setting of conformal fractional multiplicative integrals, which represent a modern extension of traditional fractional calculus.
İrem Çay   +2 more
doaj   +1 more source

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

open access: yesMolecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel   +12 more
wiley   +1 more source

Fundamental theorem of calculus: a major development for integral calculus

open access: yes, 2023
This work presents an investigation into one of the main discoveries in the history of mathematics - The Fundamental Theorem of Calculus (TFC).
Nogueira, Thalison Lopes
core  

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy